New phase 3 data show meaningful improvement in antibody-negative myasthenia gravis, for which treatment options are limited ...

Two open-label extension studies show that the FcRn blocker nipocalimab has durable efficacy and sustained symptom control ...

Seles’ first symptoms appeared suddenly around three years ago. She began having double vision and weakness in her arms and ...

Efficacy and safety of subcutaneous self-administered gefurulimab in generalized myasthenia gravis: topline results from a ...

SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor ...

SAN FRANCISCO -- Two studies demonstrated the benefits of treating juvenile myasthenia gravis (MG) with newer drugs.

Early and accurate diagnosis holds immense importance as it allows for timely treatment to manage symptoms and enhance patients' quality of life, even in the absence of a cure. Tecan, with 40 years of ...

A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s ...

New York, July 01, 2022 (GLOBE NEWSWIRE) -- According to one of the statistics published by the National Center for Biotechnology Information (NCBI), the prevalence rate for Myasthenia Gravis (MG) ...

The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and ...

DUBLIN--(BUSINESS WIRE)--The "Myasthenia Gravis: Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. Myasthenia Gravis: Epidemiology Forecast to 2028 ...

New York, July 01, 2022 (GLOBE NEWSWIRE) -- According to one of the statistics published by the National Center for Biotechnology Information (NCBI), the prevalence rate for Myasthenia Gravis (MG) ...